🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ICYMI we recently announced positive functional modulator RTY-694 as development candidate for primary sclerosing cholangitis (#PSC). Discover how our #PFM's differentiated mechanism of action has potential to improve bile composition & flow: bit.ly/48jIezp

Our CEO, Rajesh Devraj, discusses key trends disrupting the pharma industry in the latest edition of The Medicine Maker. Read the full article to hear his insights on the role of advanced discovery platforms in drug development: bit.ly/4hequtx

🎉 We’re excited to unveil our new website and share our progress towards our mission to rectify membrane protein function and restore hope for patients with serious diseases. Check it out here: bit.ly/3UKr3Sd

Join us for our Virtual R&D Event on November 21! Meet our team and learn more about how we are advancing an orally available ABCB4/BSEP targeted PFM for the treatment of PSC to the clinic. Find out more details here: bit.ly/4hNNEqQ

We are proud to support the ALDConnect 2024 Annual Meeting & Patient Learning Academy and were grateful for the opportunity to share data demonstrating reduction of toxic VLCFA levels in patient fibroblasts for our ABCD1/2 PFM program. More details here: bit.ly/3CGNG3y

At AASLD #TLM24 we're showcasing new data on the potential of positive functional modulators (#PFMs) to restore & enhance membrane protein function in hepatobiliary diseases & introducing a new translational model of cholangitis & cholestasis. More: bit.ly/4ftKlUf

Pure CLASS! No surprises here.

Thanks @BiotechTVHQ for the opportunity to discuss our #PFM approach and data with our lead candidate that supports treatment of devastating hepatobiliary diseases like PSC by reducing both cholangitis and cholestasis.

Furthermore, the productivity loss from small decrements in test validity (e.g., by adapting the test to reduce cycle time or to increase throughput) can swamp large gains in brute-force efficiency. Quality beats quantity. 6/8

I could not agree more with Jack Scannell

Investors in Padlock Therapeutics sue Bristol Myers Squibb $BMY over ‘milestone’ payments The dark side of so-called biobucks deals, featuring Michael Gilman statnews.com/2024/12/12/pad…

Thanks for the opportunity Longwood Healthcare Leaders to converse with a distinguished panel of execs who are balancing and derisking novel science, building novel platforms and bringing differentiated products to serve patients. Longwood Fund Rectify Pharma

Thanks for the opportunity Xtalks Webinars to discuss our lead program for #PSC and our #PFM platform that allows us to discover and develop oral, small molecule drugs to rectify membrane protein dysfunction.

At #EASLCongress 2025 we’re presenting data that demonstrates the potential for a B4/BSEP PFM to address the core pathology of multiple liver & biliary diseases, incl. #PrimarySclerosingCholangitis. Read more: bit.ly/4m8O2lP

🎙️Building Biotech: From the Bench to the Boardroom Raj Devraj (CEO Rectify Pharma, Venture Partner Atlas Ventures) shares hard-won lessons on capital efficiency, target validation & startup leadership. A must-listen for biotech founders. 👇 signal.nucleate.xyz/building-biote…

We’re attending the 62nd ERA - European Renal Association Congress June 4–7! We’ll present new transitional data from our cardio-renal-metabolic program addressing critical unmet needs in kidney health. More on our presentation: bit.ly/4kvrMRM #ERA25

#ICYMI: Our CEO, Rajesh Devraj, joined Sam Kessel on the Nucleate podcast to talk target validation, PFMs, and the mission driving Rectify’s work in #PSC and beyond. 🎧 Tune in: bit.ly/4dYMuqQ

Yep. This👇🏼

King is holding court y’all.

😌